Meeting
2024 ASCO Genitourinary Cancers Symposium
Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment.
Authors
Miguel Muniz
Department of Medical Oncology, Mayo Clinic, Rochester, MN
Miguel Muniz , A. Oliver Sartor , Ahmed M. Mahmoud , Jacob Orme , John Y. Kwon , Jack R. Andrews , Adam McLain Kase , Osama M Mosalem , Alan Haruo Bryce , Irbaz Bin Riaz , Matthew Thorpe , Ayse T. Kendi , Geoffrey Johnson , Praful Ravi , Eugene D. Kwon , Daniel S Childs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 175)
DOI
10.1200/JCO.2024.42.4_suppl.175
Abstract #
175
Poster Bd #
H4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Heidi Fettke
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2024 ASCO Genitourinary Cancers Symposium
The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail M. Al-Ezzi
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim